Effects of different isoforms of apoE on aggregation of the α-synuclein protein implicated in Parkinson's disease

Neuroscience Letters

Volumn 618, Issue , 2016, Pages 146-151

  Emamzadeh, Fatemeh Nouri ^a   Aojula, Harmesh ^b   McHugh, Patrick C ^c   Allsop, David ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

Author keywords

Aggregation; Apolipoprotein E; Lewy body; Parkinson's disease; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; THIOFLAVINE; APOLIPOPROTEIN E; ISOPROTEIN; PROTEIN AGGREGATE; RECOMBINANT PROTEIN;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; IMMUNOASSAY; IMMUNOBLOTTING; IN VITRO STUDY; NONHUMAN; PARKINSON DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; SIZE EXCLUSION CHROMATOGRAPHY; CHEMISTRY; METABOLISM;

ALPHA-SYNUCLEIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; PARKINSON DISEASE; PROTEIN AGGREGATES; PROTEIN ISOFORMS; RECOMBINANT PROTEINS;

EID: 84960383157     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2016.02.042     Document Type: Article

References (33)

1. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. α-Synuclein in Lewy bodies. Nature 1997, 388:839-840.
2. Anderson J.P., Walker D.E., Goldstein J.M., de Laat R., Banducci K., Caccavello R.J., Barbour R., Huang J., Kling K., Lee M., Diep L., Keim P.S., Shen X., Chataway T., Schlossmacher M.G., Seubert P., Schenk D., Sinha S., Gai W.P., Chilcote T.J. Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006, 281:29739-29752.
3. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6469-6473.
4. Houlden H., Singleton A.B. The genetics and neuropathology of Parkinson's disease. Acta Neuropathol. 2012, 124:325-338.
5. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287:1265-1269.
6. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 2002, 34:521-533.
7. Pham C.L., Cappai R. The interplay between lipids and dopamine on α-synuclein oligomerization and membrane binding. Biosci. Rep. 2013, 33. (art:e00074). 10.1042/BSR20130092.
8. Cookson M.R. α-Synuclein and neuronal cell death. Mol. Neurodegener. 2009, 4:4-9.
9. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
10. Eisenberg D.T., Kuzawa C.W., Hayes M.G. Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history. Am. J. Phys. Anthropol 2010, 143:100-111.
11. Caselli R.J., Dueck A.C., Osborne D., Sabbagh M.N., Connor D.J., Ahern G.L., Baxter L.C., Rapcsak S.Z., Shi J., Woodruff B.K., Locke D.E., Snyder C.H., Alexander G.E., Rademakers R., Reiman E.M. Longitudinal modelling of age-related memory decline and the APOE epsilon4 effect. N. Engl. J. Med 2009, 361:255-263.
12. Ma J., Yee A., Brewer H.B., Das S., Potter H. Amyloid-associated proteins 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 1994, 372:92-94.
13. Strittmatter W.J., Saunders A.M., Goedert M., Weisgraber K.H., Dong L.M., Jakes R., Huang D.Y., Pericak-Vance M., Schmechel D., Roses A.D. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:11183-11186.
14. Brecht W.J., Harris F.M., Chang S., Tesseur I., Yu G.Q., Xu Q., Dee Fish J., Wyss-Coray T., Buttini M., Mucke L., Mahley R.W., Huang Y. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci. 2004, 24:2527-2534.
15. van den Elzen P., Garg S., León L., Brigl M., Leadbetter E.A., Gumperz J.E., Dascher C.C., Cheng T.Y., Sacks F.M., Illarionov P.A., Besra G.S., Kent S.C., Moody D.B., Brenner M.B. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 2005, 437:906-910.
16. Koutsis G., Panas M., Giogkaraki E., Potagas C., Karadima G., Sfagos C., Vassilopoulos D. APOE ε4 is associated with impaired verbal learning in patients with MS. Neurology 2007, 68:546-549.
17. Ghaffar O., Reis M., Pennell N., O'Connor P., Feinstein A. APOE ε4 and the cognitive genetics of multiple sclerosis. Neurology 2010, 74:1611-1618.
18. Wilhelmus M.M., Bol J.G., Van Haastert E.S., Rozemuller A.J., Bu G., Drukarch B., Hoozemans J.J. Apolipoprotein E and LRP1 increase early in Parkinson's disease pathogenesis. Am. J. Pathol. 2011, 179:2152-2156.
19. Hayashi H., Campenot R.B., Vance D.E., Vance J.E. Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein. J. Neurosci. 2007, 27:1933-1941.
20. Gallardo G., Schluter O.M., Sudhof T.C. A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides. Nat. Neurosci. 2008, 11:301-308.
21. Williams-Gray C.H., Goris A., Saiki M., Foltynie T., Compston D.A., Sawcer S.J., Barker R.A. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J. Neurol. 2009, 256:493-498.
22. Gao J., Huang X., Park Y., Liu R., Hollenbeck A., Schatzkin A., Mailman R.B., Chen H. Apolipoprotein E genotypes and the risk of Parkinson disease. Neurobiol. Aging 2011, 32:2106. (e1-2106. e6).
23. Frikke-Schmidt R., Nordestgaard B.G., Thudium D., Moes Grønholdt M.L., Tybjaerg-Hansen A. APOE genotype predicts AD and other dementia but not ischemic cerebrovascular disease. Neurology 2001, 56:194-200.
24. Zareparsi S., Camicioli R., Sexton G., Bird T., Swanson P., Kaye J., Nutt J., Payami H. Age at onset of Parkinson disease and apolipoprotein E genotypes. Am. J. Med. Genet. 2002, 107:156-161.
25. El-Agnaf O.M.A., Salem S.A., Paleologou K.E., Curran M.D., Gibson M.J., Court J.A., Schlossmacher M.G., Allsop D. Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006, 20:419-425.
26. Hatters D.M., Zhong N., Rutenber E., Weisgraber K.H. Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. J. Mol. Biol 2006, 361:932-944.
27. Carter D.B. The interaction of amyloid-β with ApoE. Subcell. Biochem 2005, 38:255-272.
28. Choi B.K., Choi M.G., Kim J.Y., Yang Y., Lai Y., Kweon D.H., Lee N.K., Shin Y.K. Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:4087-4092.
29. El-Agnaf O.M.A., Salem S.S., Paleologou K.E., Gibson M.J., Curran M.D., Court J.A., Mann D.M.A., Ikeda S.I., Cookson M.R., Hardy J., Allsop D. α-Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003, 17:1945-1947.
30. Masuda-Suzukake M., Nonaka T., Hosokawa M., Oikawa T., Arai T., Akiyama H., Mann D.M., Hasegawa M. Prion-like spreading of pathological α-synuclein in brain. Brain 2013, 136:1128-1138.
31. Roberts H.L., Brown D.R. Seeking a mechanism for the toxicity of oligomeric α-synuclein. Biomolecules 2015, 5:282-305.
32. Maarouf C.L., Beach T.G., Adler C.H., Malek-Ahmadi M., Kokjohn T.A., Dugger B.N., Walker D.G., Shill H.A., Jacobson S.A., Sabbagh M.N., Roher A.E., Arizona Parkinson's Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology. Biomark Insights 2013, 8:19-28.
33. Rite I., Arguelles S., Venero J.L., Garcia-Rodriguez S., Ayala A., Cano J., Machado A. Proteomic identification of biomarkers in the cerebrospinal fluid in a rat model of nigrostriatal dopaminergic degeneration. J. Neurosci. Res. 2007, 85:3607-3618.